Pcoul will receive the award this Thursday, on June 20th, at a formal ceremony in the BBVA Foundation's Madrid headquarters.
DNDi is a not-for-profit research and development organization working to deliver new treatments for what are commonly known as neglected diseases, a set of 17 neglected tropical diseases and other conditions that affect hundreds of millions of people who are collectively too poor to offer a lucrative market to the pharmaceutical industry. It focuses particularly on sleeping sickness or human African trypanosomiasis, Chagas disease, leishmaniasis, filarial infections, malaria, and pediatric HIV.
DNDi was set up on the combined initiative of seven public and private institutions: Mdecins Sans Frontires/Doctors Without Borders, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Malaysian Ministry of Health, France's Institut Pasteur, Brazil's Oswaldo Cruz Foundation (Fiocruz), and the Special Program for Research and Training in Tropical Diseases of the World Health Organization.
Its strategy is to coordinate and synergize the efforts of public and private partners including pharmaceutical companies in the development, production and distribution of new treatments. DNDi has offices in Switzerland, Brazil, the Democratic Republic of the Congo, Kenya, India, Malaysia, the United States and Japan, and coordinates a partnership network that liaises with the public and private institutions involved in each project.
"DNDi's innovative collaborative model," Pcoul remarks, "has secured the increasing engagement of public and private actors, as a result of growing awareness of these urgent and neglected public health issues."
Among the organization's partners are a number of Spanish institutions including Mdecins Sans Frontires Spain, th
|Contact: Violaine Dällenbach|
Drugs for Neglected Diseases Initiative